Table 2.

Main trials in neoadjuvant endocrine therapy

Trial	n	Groups	CRR, %	BCS rate, %
P024	337	T 4 months	36	35
		L 4 months	55	45
			p < 0.001	p = 0.022
IMPACT	330	T 12 weeks	36	31
		A 12 weeks	37	44
		A+T 12 weeks	39	24
PROACT	451	T 3 months	35.4	30.8
		A 3 months	39.5	43
ACOSOG Z-1031	374	E 16–18 weeks	62.9	67.8
		L 16–18 weeks	74.8	60.8
		A 16–18 weeks	69.1	77

T = Tamoxifen; L = letrozole; E = exemestane; CRR = clinical response rate; BCS = breast-conserving surgery.